Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 743 results found since Jan 2013.
Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibodies: An Updated Review
Monoclon Antib Immunodiagn Immunother. 2023 Apr;42(2):77-94. doi: 10.1089/mab.2022.0036.ABSTRACTMonoclonal antibodies (mAbs) had received emergency use authorization for mild-to-moderate coronavirus disease 2019 (COVID-19) or for prophylaxis against COVID-19, including casirivimab plus imdevimab (C+I), bamlanivimab plus etesevimab (B+E), tixagevimab plus cilgavimab (T+CG), and sotrovimab (S) and bebtelovimab (BEB). This systematic review was done to assess the efficacy and safety of the same. PubMed, Embase, Scopus, medRxiv, bioRxiv, and FDA fact sheets were searched for the studies published between January 2021 and May 2...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - May 2, 2023 Category: Microbiology Authors: Gandham Ravi Madhavi Eerike Venugopala Rao Konda Debasis Bisoi Gerard Marshall Raj Rekha Priyadarshini Kalpana Ramanna Mali Leo Francis Chaliserry Source Type: research
